中間α-球蛋白抑制因子H4(ITIH4)重組蛋白
Recombinant Inter Alpha-Globulin Inhibitor H4 (ITIH4)
IHRP; PK120; H4P; ITIHL1; Plasma Kallikrein-Sensitive Glycoprotein; Plasma kallikrein sensitive glycoprotein 120; Inter-alpha-trypsin inhibitor family heavy chain-related protein
- 編號RPH776Ra01
- 物種Rattus norvegicus (Rat，大鼠)相同的名稱，不同的物種。
- 來源原核表達
- 宿主E.coli
- 內毒素水平<1.0EU/µg(LAL法測定)
- 亞細胞定位細胞膜, 細胞外基質
- 預測分子量58.7kDa
- 實際分子量57kDa(差異分析請參閱說明書)
- 片段與標簽Thr478~Val722 with N-terminal His and GST Tag
- 緩沖液成份20mM Tris, 150mM NaCl緩沖液（pH8.0, 含有1mM EDTA, 1mM DTT, 0.01% SKL, 5% Trehalose和Proclin300）
- 性狀凍干粉
- 純度> 90%
- 等電點6.7
- 應用Positive Control; Immunogen; SDS-PAGE; WB.
如果需要有生物活性的蛋白，請參見活性蛋白。 - 下載英文說明書 中文說明書
- 規(guī)格10μg50μg200μg1mg5mg
- 價格¥ 1200¥ 3000¥ 6000¥ 18000¥ 45000
- 欲了解實際交易價格和更多情況，請與當地經銷商聯系!
產品包裝(模擬)
產品包裝(模擬)
Figure. SDS-PAGE
通過ISO 9001、ISO 13485質量體系認證
序列
用法
Reconstitute in 20mM Tris, 150mM NaCl (pH8.0) to a concentration of 0.1-1.0 mg/mL. Do not vortex.
儲存
避免反復凍融。2-8°C不超過一個月，-80°C不超過12個月。
穩(wěn)定性
熱穩(wěn)定性以損失率顯示。損失率是由加速降解試驗決定，具體方法如下：在37°C孵育48小時，沒有顯著的降解或者沉淀產生。保質期內，在適當的條件下存儲，損失率低于5%。
增值服務
相關產品
| 編號 | 適用物種：Rattus norvegicus (Rat，大鼠) | 應用(僅供研究使用，不用于臨床診斷！) |
| RPH776Ra01 | 中間α-球蛋白抑制因子H4(ITIH4)重組蛋白 | Positive Control; Immunogen; SDS-PAGE; WB. |
| PAH776Ra01 | 中間α-球蛋白抑制因子H4(ITIH4)多克隆抗體 | WB; IHC |
| SEH776Ra | 中間α-球蛋白抑制因子H4(ITIH4)檢測試劑盒(酶聯免疫吸附試驗法) | Enzyme-linked immunosorbent assay for Antigen Detection. |
| LMH776Ra | 中間α-球蛋白抑制因子H4(ITIH4)等多因子檢測試劑盒(流式熒光發(fā)光法) | FLIA Kit for Antigen Detection. |
| KSH776Ra01 | 中間α-球蛋白抑制因子H4(ITIH4)檢測試劑盒DIY材料(酶聯免疫吸附試驗法) | Main materials for "Do It (ELISA Kit) Yourself". |
參考文獻
| 雜志 | 參考文獻 |
| Toxicology Letters | Biomarkers for methotrexate-induced liver injury: urinary protein profiling of psoriasis patients.[Pubmed: 23830989] |
| International Journal of Medical Microbiology | Proteomic demonstration of the recurrent presence of inter-alpha-inhibitor H4 heavy-chain during aspergillosis induced in an animal model[Pubmed:24360996] |
| Cancer Research and Treatment | Inter-alpha Inhibitor H4 as a Potential Biomarker Predicting the Treatment Outcomes in Patients with Hepatocellular Carcinoma[pubmed:28724284] |
| Diagnostics | Systemic Alterations of Immune Response-Related Proteins during Glaucoma Development in the Murine Model DBA/2J[Pubmed: 32585848] |
| Liver Cancer | Biomarkers for locally advanced hepatocellular carcinoma patients treated with liver-directed combined radiotherapy[] |